Navigation Links
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW

ee studies with LIALDA as sole therapy (abstract # T1297)

Another post-hoc analysis assessed long-term remission and relapse rates (secondary endpoints) of study 303. The analysis evaluated data from patients taking Lialda from all three studies: 301, 302, and 303. Patients in the parent studies (301 and 302) who did not achieve remission after eight weeks on Lialda were eligible for enrollment in the acute phase of study 303. In this acute phase, they were given a higher dose of Lialda (4.8g/day, once daily) for an additional eight weeks to induce remission. In total, 63.6 percent of patients (n=220/346) treated with Lialda for up to 16 weeks achieved remission.

Those patients, who achieved remission either in the parent studies (n=125), or the acute phase of study 303 (n=95), were allowed to enter the 12-month maintenance phase of study 303. Of the 220 patients who were in remission, 218 patients actually entered the maintenance phase.

A combined analysis of both long-term remission rates and relapse rates showed that of the patients who started on Lialda therapy, 56.6 percent achieved remission and remained relapse free for at least one year.

About LIALDA

LIALDA is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of LIALDA have been established for up to eight weeks. LIALDA is the first new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipie
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
(Date:8/3/2015)... 3, 2015 Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: ... Daniel Teper , will present live at VirtualInvestorConferences.com on ... TIME:   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... event where investors are invited to ask the company ... as well as the association,s "virtual trade booth." If ...
(Date:8/3/2015)... Shire plc (LSE: SHP, ... has acquired New York -based, ... With the acquisition, Shire acquires the global rights ... iodine (PVP-I) and 0.1% dexamethasone), a therapy in ... an ocular surface condition commonly referred to as ...
(Date:8/2/2015)... 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... 3 clinical trial met its primary endpoint, showing ... cancer patients with carcinoid syndrome that is not ... Telotristat etiprate was discovered using Lexicon,s gene science, ... company,s first discovery to complete a pivotal Phase ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... NEW ORLEANS, June 6 Eli Lilly and Company (NYSE: ... study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) ... diabetes. These data will be presented as part of the ... , , In the Phase II study, ...
... American Diabetes Association,s 69th Scientific Sessions shows investigational ... function tests , , NEW ORLEANS, June ... Powder is a well-tolerated, ultra rapid acting insulin ... usual antidiabetic treatment, according to data presented today ...
Cached Medicine Technology:Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 2Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 3Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 4AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 2AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 3
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The art ... experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely ... has decided to share her cookbook Recipes from My Persian Kitchen with the world. ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its least visited ... untapped ground water aquifers, whose main outflow is at Ahjumawi Lava Springs, part ...
(Date:8/3/2015)... ... ... From 2006-2017 the number of dental laboratories in the ... for the National Association of Dental Laboratories ( NADL ) by Valmont Research ... As the number of dental laboratories decreases, dentists will have fewer options when ...
(Date:8/3/2015)... ... , ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing ... years of suffering and using medications with strong side effects. This had already forced ... time off or wait longer hours in the waiting rooms. Instead, he went home ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Code Council (ICC) announce an agreement to collaborate across a wide range ... to increasing building code knowledge among architects. , “Our combined membership, consisting of ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3
... suicidal thoughts as well, study finds , TUESDAY, June 9 ... bed at 10 p.m. are less apt to become depressed ... much later, recent research shows. , "This study bolsters the ... study author James Gangwisch, an assistant professor of psychiatry at ...
... LANCASTER, Pa., June 9 Herley Industries, Inc. (Nasdaq: ... Lancaster division received a contract award valued at approximately ... manufacture complex Integrated Microwave Assemblies (IMA) for an electronic ... Herley Chairman and CEO, Myron Levy, said, "Herley has ...
... professional pilots for example, depend on good vision as ... not required to undergo regular vision testing. A new ... they don,t recall ever having their vision tested or ... last vision exam. The study, performed at ...
... This release is available in French . ... antifungals are seeping into the waterways of North America, ... in the peer-reviewed journal Environmental Health Perspectives ... researchers, the review found that consumption of anti-infectives for ...
... unions, and veteran political leaders announces support for ... improve outcomes and reduce health care costs for ... support bipartisan reform agreement in Congress , ... an organization bringing together an expanding alliance of ...
... First Sugar-Free Functional Beverage Made Specifically for Kids, Over Soda ... WAT-AAH!, the first sugar-free functional beverage brand made specifically for ... their first nationwide WAT-AAH! Challenge to defy the expectation that ... over water. , , During the months of ...
Cached Medicine News:Health News:Early Bedtime May Help Stave Off Teen Depression 2Health News:Early Bedtime May Help Stave Off Teen Depression 3Health News:Herley Receives a $1.2 Million Contract Award for Complex Integrated Microwave Assemblies for U.S. Electronic Attack Aircraft 2Health News:Antibiotics, antimicrobials and antifungals in waterways 2Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 2Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 3Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 4Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 5Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 6Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 7Health News:Let Water Be Water, LLC Announces Results of the 'WAT-AAH! Challenge' 2
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... Para 12 is a three-part differential control assayed ... STKR, J Series, T Series, AcT/AcT diff/AcT diff2, ... 1500, 1600, 1700, and 1800; Danam Datacell18, Datacell ... I-1800, I-1800MS/MS PLUS and I-1600; the ABX Micros ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: